191 related articles for article (PubMed ID: 38570866)
1. Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET.
Xia S; Duan W; Xu M; Li M; Tang M; Wei S; Lin M; Li E; Liu W; Wang Q
J Exp Clin Cancer Res; 2024 Apr; 43(1):103. PubMed ID: 38570866
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.
He X; Wang L; Riedel H; Wang K; Yang Y; Dinu CZ; Rojanasakul Y
Mol Cancer; 2017 Mar; 16(1):63. PubMed ID: 28288645
[TBL] [Abstract][Full Text] [Related]
3. AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Liu W; Song J; Du X; Zhou Y; Li Y; Li R; Lyu L; He Y; Hao J; Ben J; Wang W; Shi H; Wang Q
Acta Biomater; 2019 Jun; 91():195-208. PubMed ID: 31034948
[TBL] [Abstract][Full Text] [Related]
4. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
Front Immunol; 2021; 12():628906. PubMed ID: 33777013
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway.
Wei CH; Wu G; Cai Q; Gao XC; Tong F; Zhou R; Zhang RG; Dong JH; Hu Y; Dong XR
J Hematol Oncol; 2017 Jun; 10(1):125. PubMed ID: 28629431
[TBL] [Abstract][Full Text] [Related]
6. MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.
Zhu K; Lv Z; Xiong J; Zheng H; Zhang S; Jin H; Yu L; Li Z; Zhang J; Li C; Liang P
Aging (Albany NY); 2021 Feb; 13(5):6890-6903. PubMed ID: 33621951
[TBL] [Abstract][Full Text] [Related]
7. High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study.
Takamizawa S; Yazaki S; Kojima Y; Yoshida H; Kitadai R; Nishikawa T; Shimoi T; Sudo K; Okuma HS; Tanioka M; Noguchi E; Uno M; Ishikawa M; Kato T; Fujiwara Y; Yonemori K
BMC Cancer; 2022 Nov; 22(1):1215. PubMed ID: 36434635
[TBL] [Abstract][Full Text] [Related]
8. Zebrafish xenograft model for studying mechanism and treatment of non-small cell lung cancer brain metastasis.
Fan RY; Wu JQ; Liu YY; Liu XY; Qian ST; Li CY; Wei P; Song Z; He MF
J Exp Clin Cancer Res; 2021 Nov; 40(1):371. PubMed ID: 34801071
[TBL] [Abstract][Full Text] [Related]
9. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
10. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways.
Chang MC; Chen CA; Chen PJ; Chiang YC; Chen YL; Mao TL; Lin HW; Lin Chiang WH; Cheng WF
Biochem J; 2012 Mar; 442(2):293-302. PubMed ID: 21999204
[TBL] [Abstract][Full Text] [Related]
11. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
[TBL] [Abstract][Full Text] [Related]
12. Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway.
Huo Q; Xu C; Shao Y; Yu Q; Huang L; Liu Y; Bao H
Int J Biol Sci; 2021; 17(2):574-588. PubMed ID: 33613114
[No Abstract] [Full Text] [Related]
13. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
Zhu Y; Zuo D; Wang K; Lan S; He H; Chen L; Chen X; Feng M
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15027-15038. PubMed ID: 37612388
[TBL] [Abstract][Full Text] [Related]
14. MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer.
Ramesh S; Cifci A; Javeri S; Minne RL; Longhurst CA; Nickel KP; Kimple RJ; Baschnagel AM
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1379-1390. PubMed ID: 37979706
[TBL] [Abstract][Full Text] [Related]
15. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.
Kachala SS; Bograd AJ; Villena-Vargas J; Suzuki K; Servais EL; Kadota K; Chou J; Sima CS; Vertes E; Rusch VW; Travis WD; Sadelain M; Adusumilli PS
Clin Cancer Res; 2014 Feb; 20(4):1020-8. PubMed ID: 24334761
[TBL] [Abstract][Full Text] [Related]
16. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Martinez-Marti A; Felip E; Matito J; Mereu E; Navarro A; Cedrés S; Pardo N; Martinez de Castro A; Remon J; Miquel JM; Guillaumet-Adkins A; Nadal E; Rodriguez-Esteban G; Arqués O; Fasani R; Nuciforo P; Heyn H; Villanueva A; Palmer HG; Vivancos A
Ann Oncol; 2017 Oct; 28(10):2451-2457. PubMed ID: 28961841
[TBL] [Abstract][Full Text] [Related]
17. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
Awuah P; Bera TK; Folivi M; Chertov O; Pastan I
Mol Cancer Ther; 2016 Jul; 15(7):1648-55. PubMed ID: 27196771
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer.
Yoshida T; Oya Y; Tanaka K; Shimizu J; Horio Y; Kuroda H; Sakao Y; Hida T; Yatabe Y
Lung Cancer; 2016 Jul; 97():43-7. PubMed ID: 27237026
[TBL] [Abstract][Full Text] [Related]
19. Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer.
Guo J; Zeng X; Zhu Y; Yang D; Zhao X
J Transl Med; 2024 Apr; 22(1):367. PubMed ID: 38637885
[TBL] [Abstract][Full Text] [Related]
20. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
